Business
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
(TheNewswire) Multiple patients with sustained clinical benefit, including po...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Multiple patients\nwith sustained clinical benefit, including positive fasting serum\nC-peptide (a biomarker of insulin produced by Sernova’s Cell Pouch\nislets) detected in their bloodstream\n \n \n \n \n LONDON,\n \n \n ONTARIO\n \n \n –\n \n \n TheNewswire -\n \n \n June\n \n \n 7,\n \n \n 2021\n \n \n –\n \n \n Sernova\n \n \n Corp.\n \n \n (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH),\n \n \n a leading clinical-stage regenerative medicine therapeutics\ncompany today announced that its principal investigator, Dr. Piotr\nWitkowski, presented new preliminary data from Sernova’s ongoing\nU.S. Phase I/II T1D  clinical trial at the University of Chicago. Dr.\nWitkowski’s presented the data at the American Transplant Congress\n(ATC) 2021 Virtual Connect conference on Saturday June 5, 2021.\n \n \n \n \n The overall objective of the clinical trial is to\nassess the safety, tolerability, and efficacy of the Cell Pouch with\ninsulin-producing islets. In addition to other criteria, prior to\nentry into the study, the patients must demonstrate long-standing T1D\nwith severe hypoglycemic unawareness episodes and no\nglucose-stimulated C-peptide circulating in their bloodstream.\n \n \n \n \n Dr. Witkowski’s presentation entitled\n \n \n “Islet Allotransplantation\nInto The Pre-Vascularized Sernova Cell Pouch\n \n \n TM\n \n \n Device - Preliminary Results Of The Phase\nI/II Prospective, Open-Label, Single-Arm Study At University of\nChicago”\n \n \n highlighted the following key\npoints:\n \n \n \n \n \n \n - 6 patients are implanted with Cell Pouches and\ncontinue to meet the study’s primary safety endpoint;\n \n \n \n \n - 5 patients have now been transplanted with at least\none dose of therapeutic cells (insulin producing islets) and are in\ndifferent stages of the clinical trial; and\n \n \n \n \n - most significantly,\n \n \n \n \n positive fasting serum C-peptide\nhas been detected in the bloodstream of 4 patients so far. C-peptide\nis a biomarker for insulin produced by the islets in the Cell\nPouch\n \n \n .\n \n \n \n \n \n \n In addition to the continued confirmation of on...